News round-up for 11-15 November by DDW Senior Digital Content Editor Diana Spencer.

With the Society for Immunotherapy of Cancer (SITC) 2024 taking place in Houston recently, there have been a number of recent announcements regarding the clinical advancement of immunocytokines, METTL3 inhibitors, cancer vaccines, CAR-T therapies and immune checkpoint inhibitors for the treatment of cancer.

The top stories:

PD-1-targeting immunocytokine reinvigorates T cells

New data supporting SOT201, a PD-1-targeting immunocytokine, in advanced solid tumours was presented at the 2024 Society for Immunotherapy of Cancer (SITC) Meeting in Houston, TX, US.

New clinical data on first-in-class METTL3 inhibitor

Storm Therapeutics has presented promising data from its Phase I clinical study evaluating its METTL3 RNA methyltransferase inhibitor, STC-15, at the Society of Immunotherapy for Cancer (SITC) 39)th Annual Meeting, held in Houston, US, from 6-10 November 2024.

Breakthroughs on cancer vaccine development at SITC 2024

Infinitopes presented three posters on its cancer vaccine discovery and development strategy, including one that has been recognised as a ‘top 100’ poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10 November.

First FDA approval for new CAR-T therapy

The US Food and Drug Administration (FDA) has approved Autolus’ obecabtagene autoleucel (Aucatzyl), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).

Immunotherapy with chemotherapy effective for rare cancers

New research has found that combining immunotherapy with chemotherapy is safe and effective for people with advanced small cell cancers in the bladder and prostate.